JHVEPhoto The Oregon attorney general is asking a judge to delay Paramount Skydance's ( PSKY ) planned $110 billion purchase of Warner Bros. Discovery ( WBD ) as he seeks documents related to a state probe of the mega media deal. Oregon Attorney General Dan Rayfield is asking a Multnomah County judge to delay the deal from closing for 60 days while the state reviews the company’s records, accordin...
JHVEPhoto The Oregon attorney general is asking a judge to delay Paramount Skydance's ( PSKY ) planned $110 billion purchase of Warner Bros. Discovery ( WBD ) as he seeks documents related to a state probe of the mega media deal. Oregon Attorney General Dan Rayfield is asking a Multnomah County judge to delay the deal from closing for 60 days while the state reviews the company’s records, according to a statement on Tuesday. Rayfield wants Paramount ( PSKY ) to turn over documents related to an Oregon Department of Justice probe into its proposed purchase of Warner Bros. ( WBD ). “We’re not going to let Paramount Skydance play hide the ball so they can rush through their massive merger,” said Attorney General Dan Rayfield. “Oregonians have a real stake in this deal – in our film industry, in our economy, in the choices they’ll have as consumers. Paramount had every opportunity to hand over records and answer a few basic questions. Instead, it is trying to run out the clock and evade scrutiny. We’re asking the court to make sure Oregonians get the answers they’re owed before this deal closes, not after.” Oregon has been looking at the deal since it was announced in February. The state's DOJ sent Paramount ( PSKY ) a records request in June, asking for documents about the company’s lobbying of federal officials in support of the transaction, its role in a U.S. Department of Justice statement approving the merger, and an internal effort the company calls “Project Warrior.” The Oregon DOJ plans to present its motion in person in Multnomah County Court on Wednesday. CNBC's David Faber earlier Wednesday downplayed the Oregon request and said he's focused on whether the California AG will file a lawsuit. "I'm just not even going to focus on this, frankly, " Faber said on the business network. "We're waiting on California. We'll see whether they actually make their move in terms of seeking an injunction." Faber on Monday reported that California hired a law firm for a poten...
Palantir Technologies stock slid Wednesday after a Financial Times report raised concerns about the company’s political standing, while shares also ran into technical resistance following a sharp rebound.
Palantir Technologies stock slid Wednesday after a Financial Times report raised concerns about the company’s political standing, while shares also ran into technical resistance following a sharp rebound.
PrathanChorruangsak/iStock via Getty Images The current market trajectory has resulted in increasing the appeal of low-duration asset classes, due to the cautious outlook on interest rates largely due to inflationary pressures and central banks' primary emphasis on keeping inflation in line with target rates. While it doesn't suggest conclusively that long-duration assets might be unattractive sin...
PrathanChorruangsak/iStock via Getty Images The current market trajectory has resulted in increasing the appeal of low-duration asset classes, due to the cautious outlook on interest rates largely due to inflationary pressures and central banks' primary emphasis on keeping inflation in line with target rates. While it doesn't suggest conclusively that long-duration assets might be unattractive since the rates are still high and the yield curve is still positively sloping; however, for investors who are not desirous of exposing themselves to the sensitivities arising from interest rates, they may find certain value in vehicles such as the JPMorgan Limited Duration Bond ETF ( JPLD ). The fund remains a low-duration vehicle; its expense ratio is at moderate levels, and it allocates to higher credit-rated issues, presenting an allocation case primarily for conservative investors either as a yield parking proposition or a cash-plus allocation. Fund Overview JPLD is an actively managed fixed income fund emphasizing low-duration fixed income allocations. The AUM for the fund stands at around ~3.94 billion. The fund at present has a 30-day SEC yield of ~4.4% and a trailing dividend yield of ~4.27% , broadly in line with its SEC yield. The primary focus of the fund and the value that it might offer to an investor is its allocations to mortgage-related securities, MBS, ABS and the use of certain derivatives. The profile of the fund, however, would remain on the conservative side at large. The duration of the fund stands at ~2.05 years for the present, consistent with the mandate of the fund. JPLD fact-sheet Although the fund states that it largely invests in mortgage-related securities, agency MBS, and asset-backed securities for generating incremental return for an investor. However, a considerable portion of the investments is still held in Treasuries, enhancing the stability of the allocation. For example, at the end of May , the fund had over ~30% exposure to Treasuries a...
Motley Fool co-founder and CEO Tom Gardner shares five long-term stock ideas -- but first lays out three "outrageous" statements about how he believes investors should approach today's market. Also in this video: Five companies Gardner highlights for a diversified, long-term portfolio: Cisco Systems (NASDAQ: CSCO) , MSCI (NYSE: MSCI) , Kingstone Companies (NASDAQ: KINS) , Marvell Technology (NASDA...
Motley Fool co-founder and CEO Tom Gardner shares five long-term stock ideas -- but first lays out three "outrageous" statements about how he believes investors should approach today's market. Also in this video: Five companies Gardner highlights for a diversified, long-term portfolio: Cisco Systems (NASDAQ: CSCO) , MSCI (NYSE: MSCI) , Kingstone Companies (NASDAQ: KINS) , Marvell Technology (NASDAQ: MRVL) , and BillionToOne (NASDAQ: BLLN) . Continue reading
JHVEPhoto/iStock Editorial via Getty Images The European Commission on Wednesday announced that Sanofi ( SNY ) has agreed to stop disparaging a rival flu vaccine developed by CSL Limited ( CSLLY ) after the French drugmaker faced an EU antitrust probe into its marketing campaign that promoted its own Efluelda vaccine. Last month, the EU antitrust officials launched an investigation into whether Sa...
JHVEPhoto/iStock Editorial via Getty Images The European Commission on Wednesday announced that Sanofi ( SNY ) has agreed to stop disparaging a rival flu vaccine developed by CSL Limited ( CSLLY ) after the French drugmaker faced an EU antitrust probe into its marketing campaign that promoted its own Efluelda vaccine. Last month, the EU antitrust officials launched an investigation into whether Sanofi ( SNY ) breached competition rules by conducting what it called a “misleading communication campaign” since 2024 targeting CSL’s ( CMXHF ) Fluad. Fluad and Efluelda are enhanced flu shots, indicated in Europe for elderly people to protect them against the influenza virus. As part of the campaign, Sanofi ( SNY ) allegedly claimed that Fluad is weaker than Efluelda, contradicting findings of national immunization technical advisory groups (NITAGs) in Germany and France. To address the concerns, the Paris-based drugmaker has made a series of commitments, including publishing statements clarifying that the current recommendations of German and French NITAGs treat Efluelda and Fluad equally for elderly people. The regulator has opened a public comment period until August 21 to allow interested parties to submit their views on the proposals, which it said will remain in effect through March 2030. More on Sanofi, Sanofi, etc. Sanofi 'Strong Buy': Continued Dupxient Sales Growth And Sarclisa OBI First CSL Limited (CSLLY) Shareholder/Analyst Call Transcript CSL Limited (CSLLY) Shareholder/Analyst Call - Slideshow Sanofi's Nexviazyme hits primary goal in Pompe disease study Lilly, Incyte, CSL among winners of EU drug recommendations this week
Oregon’s attorney general is seeking a court order for Paramount Skydance Corp. to hand over documents related to lobbying for its $110 billion takeover of Warner Bros. Discovery Inc. and to delay closing the deal for 60 days while the state continues its antitrust probe. Paramount has been “dodging and delaying” a “straightforward” subpoena for merger-related documents while “racing to close its ...
Oregon’s attorney general is seeking a court order for Paramount Skydance Corp. to hand over documents related to lobbying for its $110 billion takeover of Warner Bros. Discovery Inc. and to delay closing the deal for 60 days while the state continues its antitrust probe. Paramount has been “dodging and delaying” a “straightforward” subpoena for merger-related documents while “racing to close its deal” before the state can finish its investigation, Oregon Attorney General Dan Rayfield said in a statement Tuesday night. “We’re not going to let Paramount Skydance play hide the ball so they can rush through their massive merger,” Rayfield, a Democrat, said in the statement. “Oregonians have a real stake in this deal – in our film industry, in our economy, in the choices they’ll have as consumers.” The US Justice Department last month closed its probe into the Hollywood mega-deal, saying the deal “is not likely” to hurt consumers or competition in the film and television industry. Even so, the top lawyers for several states have been drafting a legal challenge , laying the groundwork for an antitrust suit, people familiar with the matter said last month. Paramount so far has only committed to refrain from closing the deal through July 16, according to Oregon. A Paramount spokesperson said the company has provided Rayfield’s office “with all relevant documents it requested for the merger” and will “vigorously defend” in court any attempts to delay the deal. “The information the Oregon Department of Justice is seeking has nothing to do with whether this transaction complies with Oregon’s antitrust laws and is not a legitimate basis to delay a plainly lawful, pro-competitive transaction,” the spokesperson said. Oregon has been investigating the proposed merger since it was announced in February. As part of that work, the state sent Paramount a records request in June, seeking documents about the company’s lobbying of federal officials in support of the deal and any role it...
Apple (AAPL) and Broadcom (AVGO) are partnering on a $30 billion AI chip deal. Yahoo Finance Technology Editor Dan Howley explains more in the video above.
Apple (AAPL) and Broadcom (AVGO) are partnering on a $30 billion AI chip deal. Yahoo Finance Technology Editor Dan Howley explains more in the video above.
jetcityimage/iStock Editorial via Getty Images Chevron ( CVX ) announced Wednesday a technology licensing agreement with enhanced oil recovery supply and technology company ZL Chemicals that allows ZL to commercialize Chevron-developed chemical surfactant technology. Chevron ( CVX ) said it has developed and applied surfactant technology to improve resource recovery in unconventional reservoirs, a...
jetcityimage/iStock Editorial via Getty Images Chevron ( CVX ) announced Wednesday a technology licensing agreement with enhanced oil recovery supply and technology company ZL Chemicals that allows ZL to commercialize Chevron-developed chemical surfactant technology. Chevron ( CVX ) said it has developed and applied surfactant technology to improve resource recovery in unconventional reservoirs, and the licensing agreement allows for broader commercial use of the technology. Under the agreement, ZL will commercialize and market products and services under the Vantis brand utilizing the licensed technology, which is expected to support applications in shale and tight reservoirs, including base well enhanced oil recovery programs and new well optimization efforts. The chemicals that are being licensed to ZL have improved production from newly drilled wells by as much as 20% during the first year and reduced production decline in existing wells by 5%-8%, Chevron's ( CVX ) Chief Technology and Engineering Officer Ryder Booth told Reuters in an interview. "With constraints on energy in the world today, there's a call on oil and gas companies to get more energy to market. This is a way that we can answer the call to help boost production," Booth said. More on Chevron 2026 2H Oil Dividend Roundup: Chevron Outshines Enterprise Products Partners Chevron's Microsoft AI Deal Could Be The Blueprint For A New Growth Engine (Rating Upgrade) Chevron Presents at J.P. Morgan Natural Resources Conference 2026 Transcript
Kostyuk beats Paolini in straight sets Noskova defeats Elise Mertens 6-3, 7-5 A lot has been made of how open the women’s draw at Wimbledon is this year, even before the defending champion Iga Swiatek and the world’s top two, Aryna Sabalenka and Elena Rybakina, all fell in the first week . But sometimes it pays to be aware of the in-form players, whoever they are, and so it was no surprise to see ...
Kostyuk beats Paolini in straight sets Noskova defeats Elise Mertens 6-3, 7-5 A lot has been made of how open the women’s draw at Wimbledon is this year, even before the defending champion Iga Swiatek and the world’s top two, Aryna Sabalenka and Elena Rybakina, all fell in the first week . But sometimes it pays to be aware of the in-form players, whoever they are, and so it was no surprise to see Marta Kostyuk and Linda Noskova march into the semi-finals. Kostyuk, the Ukrainian 12th seed who reached the semi-finals at the French Open last month, crushed the 2024 runner-up Jasmine Paolini 6-3, 6-2 on Centre Court while the 21-year-old Noskova, seeded ninth, saw off Elise Mertens of Belgium 6-3, 7-5 to make it 10 wins out of 11 on grass this year. Continue reading...
Pla2na/iStock via Getty Images Topline Summary and Update When last I left off with Fate Therapeutics, Inc. ( FATE ) in May 2025, I lamented the challenges that the company was facing as they continued their pivot into CAR T-cell therapy for autoimmune disease in the context of a heavily depressed sentiment on cell therapy companies on the whole. In that, I saw some substantial opportunity for FAT...
Pla2na/iStock via Getty Images Topline Summary and Update When last I left off with Fate Therapeutics, Inc. ( FATE ) in May 2025, I lamented the challenges that the company was facing as they continued their pivot into CAR T-cell therapy for autoimmune disease in the context of a heavily depressed sentiment on cell therapy companies on the whole. In that, I saw some substantial opportunity for FATE, as well, which has so far been shown to be a good prediction. The stock is up approximately 190% since the last article and stands at a market cap of around $300 million at the time of writing. Today, I want to take another look at FATE as they have been able to mature their cell therapy pipeline by another year. As the market has gained confidence, is there further upside from here? Pipeline Updates FT819 FATE started its life as an oncology-focused cell therapy biotech, but in the last few years it has made a nearly full pivot into the development of CD19-directed CAR T-cell therapy for autoimmune disease. I've touched on what we've seen out of early trials for FT819, a stem cell-derived “non-self” CAR T-cell product that can induce reductions of B cells with eliminated risk of graft-versus-host disease. Specifically, we had seen early findings in the setting of systemic lupus erythematosus (SLE) in a phase 1 trial showing that patients could achieve sustained depletion of B cells, as well as early signals that patients could have remission without ongoing immunosuppressant treatment. Since then, FATE has planned a move for FT819 into a registrational study called RECLAIM-LN , focused on evaluating the efficacy and safety of FT819 in patients with lupus nephritis. The company has guided that this trial is on track to officially begin in the second half of 2026. An ongoing phase 1 study called FT819-102 is also evaluating the use of FT819 in various autoimmune diseases, but using a conditioning regimen that lacks fludarabine (the conditioning regimen is the chemotherapy...
cookelma/iStock via Getty Images Photronics ( PLAB ) is a U.S. company within the semiconductor value chain that drew my attention. Having previously covered a lot of companies in data infrastructure and also chip manufacturing, I view PLAB as a beneficiary of the secular AI tailwinds, since it essentially manufactures equipment used in the chip-making process. Q1 presentation To be more precise, ...
cookelma/iStock via Getty Images Photronics ( PLAB ) is a U.S. company within the semiconductor value chain that drew my attention. Having previously covered a lot of companies in data infrastructure and also chip manufacturing, I view PLAB as a beneficiary of the secular AI tailwinds, since it essentially manufactures equipment used in the chip-making process. Q1 presentation To be more precise, PLAB manufactures not just FPD (flat panel display) but also IC (integrated circuit) photomasks, which are high-precision stencils used in photolithography to print microscopic patterns onto silicon wafers. It generates revenue by selling these custom-engineered equipment to chip makers like Samsung. Since this is a highly specific and technical area of chip manufacturing, my sense is that PLAB could be an underrated play in this space, where it competes with mostly Japanese companies like Tekscend Photomasks and Dai Nippon. google Since its IPO in 1987, PLAB has seen a rather cyclical share performance, generating an almost 800% return, which on an annual basis is not attractive enough, in my view. Share price has more than doubled to $27.6 per share in the past five years, suggesting that there seems to be a long-term positive sentiment as of late. Yet, PLAB is currently down -17.5% YTD, marked by a sharp correction from the $50 level late last month. I initiate my coverage with a buy rating. My FY 2026 price target analysis projects around 16% upside. PLAB remains an interesting long-term opportunity in my view, and given the pronounced correction, I believe that any signs of tape-out activities recovery could equally drive pronounced positive sentiments, making PLAB today appear undervalued. Financial Reviews Fundamentals have been rather underwhelming as of Q2 2026, which would explain the recent negative sentiments on the stock as of late. Q1 presentation Top-line performance has gotten worse YoY, with Q2 revenue down -0.5% YoY to $209 million, though the management s...